How do you introduce a Swiss biotech with an emerging clinical pipeline in a crowded oncology space to U.S. investors while still demonstrating value with the current catalyst and value drivers? SmithSolve defined its corporate story, branded its image and raised its corporate visibility.

Assignment

  • Introduce, explain DARPin® technology platform to highlight its value, potential and future opps.
  • Show clinical, commercial potential of abicipar and upcoming DARPin® compounds
  • Highlight emerging pipeline in oncology and demonstrate potential even at an early stage
  • Differentiate and better communicate the DARPin® technology to all key stakeholders
  • Build investor confidence in pipeline and help attract capital

Slved

Solved

  • Worked with management team to structure event flow by anticipating areas of high interest
  • Provided feedback to presentation to highlight new data to show potential of platform and to ensure it was presented in a clear, understandable and consistent way
  • Coordinated KOL participation to provide credibility to disease states
  • Developed materials to introduce new technology, including: boilerplate, core messages document, and revised website copy to ensure consistency across platforms
  • Developed Q&A to guide management team through tough questions

Results

  • Attracted 52 investors in-person
  • Secured 35 participants via webcast
  • Consistent corporate materials along with corporate branding
  • Secured positive feedback from post-event survey regarding event flow, content, value

“A very warm welcome from my side. It’s a great pleasure to be here in New York for the first ever R&D Day of Molecular Partners. I’m very happy and grateful to be here and showcase our pipeline — we’re opening a new chapter for our company.” – Patrick Amstutz, chief executive officer of Molecular Partners